ArticleInvestigational new drugs2015

A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer.

Zahi Mitri et al.PubMed ↗Publisher ↗

No numbers read from the abstract.